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Abstract: 
Molecular docking is routinely used for understanding drug–receptor interaction in modern drug design. Here, we describe the 
docking of 2, 4-diamino-5-methyl-5-deazapteridine (DMDP) derivatives as inhibitors to human dihydrofolate reductase (DHFR). 
We docked 78 DMDP derivates collected from literature to DHFR and studied their specific interactions with DHFR. A new 
shape-based method, LigandFit, was used for docking DMDP derivatives into DHFR active sites.  The result indicates that the 
molecular docking approach is reliable and produces a good correlation coefficient (r
2
 = 0.499) for the 73 compounds between 
docking score and IC50 values (Inhibitory Activity).  The chloro substituted naphthyl ring of compound 63 makes significant 
hydrophobic contact with Leu 22, Phe 31 and Pro 61 of the DHFR active site leading to enhanced inhibition of the enzyme. The 
docked complexes provide better insights to design more potent DHFR inhibitors prior to their synthesis. 
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Background: 
Folate metabolism has long been recognized as an 
attractive target for cancer chemotherapy because of its 
indispensable role in the biosynthesis of nucleic acid 
precursors  [1]. Within folate metabolism, Dihydrofolate 
reductase (DHFR) which catalyzes the reduction of folate 
or 7, 8-dihydrofolate to tetrahydrofolate and intimately 
couples with thymidylate synthase has been of particular 
interest. The DHFR is present in all cells and is necessary 
for the maintenance of intracellular folate pools in a 
biochemically active reduced state [2]. Inhibition results in 
depletion of intracellular reduced folates, which are 
necessary for one carbon transfer reactions. One carbon 
transfer reactions are important for the biosynthesis of 
thymidylate, purine nucleotides, methionine, serine, 
glycine and many other compounds necessary for RNA, 
DNA and protein synthesis [3]. Therefore, DHFR 
represents an attractive target for developing antitumor 
agents.  
 
Several DHFR inhibitors, as separate entities, have found 
clinical utility as antitumor agents [4]. The classical 
antifolate like methotrexate (MTX) has been used 
clinically for more than 50 years.  Because of the frequent 
occurrence of tumor resistance and ineffectiveness against 
many solid tumors, extensive structural modifications of 
MTX have been reported to improve its antitumor 
spectrum of activity and to circumvent tumor resistance. 
[5] However, none of these modified analogues showed 
better DHFR inhibitory or antitumor activity than MTX. In 
addition, they require an active transport mechanism to 
enter cells, which, when impaired, causes resistance. In an 
attempt to overcome these potential drawbacks, non classical 
lipophilic antifolates have been developed as antitumor agents 
which do not require the folate transport system(s) and enter 
cells via diffusion. One such group is the derivatives of 2, 4-
diamino-5-methyl-5-deazapteridine (DMDP) having structures 
similar to the trimetrexate/piritrexim class of antifolates. Due to 
an interest in new anticancer drugs, several DMDP inhibitors 
were chosen from the Southern Research Institute chemical 
repository for screening against human DHFR [6]. 
 
Nowadays, molecular docking approaches are routinely used in 
modern drug design to help understand drug–receptor 
interaction. It has been shown in the literature that these 
computational techniques can strongly support and help the 
design of novel, more potent inhibitors by revealing the 
mechanism of drug–-receptor interaction. However, so far, 
there has been no report concerning the application of 
molecular docking methodology for understanding the binding 
of DMDP derivatives. 
 
In this study, we have used docking studies to study the binding 
orientations of DMDP derivatives to human DHFR. Such 
studies have been carried out to understand the forms of 
interaction of seventy eight compounds, synthesized by Suling 
and colleagues [6] for the human DHFR. The results obtained 
from this study would be useful in both understanding the 
inhibitory mode of the DMDP derivatives as well as in rapidly 
and accurately predicting the activities of newly designed 
inhibitors on the basis of docking scores. These models also Bioinformation by Biomedical Informatics Publishing Group                                             open access 
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provide some beneficial clues in structural modification for 
designing new inhibitors for the treatment of cancer with 
much higher inhibitory activities against DHFR. 
 
Methodology: 
Molecular structures and optimization 
The biological activity data of DMDP derivatives (Seventy 
Eight molecules), reported by Suling and colleagues [6] 
was used in the present study (Table 1 under 
supplementary material). The structures of all the 
compounds were constructed using the InsightII 2000.1 
Builder module (http://www.accelrys.com). The 
geometries of these compounds were subsequently 
optimized using Discover module of InsightII 2000.1 using 
CVFF force field. The structure of human DHFR protein 
(PDBid code 1KMS) was obtained from Protein Data 
Bank.     
  
Molecular docking 
Molecular docking of DMDP derivatives to the active site 
of human DHFR was carried out using modern docking 
engine LigandFit available with Cerius2_4.9. 
(http://www.accelrys.com). This algorithm makes use of a 
cavity detection algorithm for detecting invaginations in 
the protein as potential active site regions. A shape 
comparison filter is combined with a Monte Carlo 
conformational search for generating ligand poses 
consistent with the active site shape. Candidate poses are 
minimized in the context of the active site using a grid-
based method for evaluating protein-ligand interaction 
energies. The docking was carried out with the following 
non default settings in LigandFit: site partitioning in order 
to fully access the potential docking orientation of the 
active site, maximum trials variable table values to help the 
pseudorandom conformational analysis, and the CFF force 
field [8] option was used for the grid energy calculations. 
The flexible fitting option was selected for generation of 
alternative conformations on the fly, as was the diverse 
conformer's option to ensure the solutions generated covers 
a broad range of conformations with similar low-energy 
docking scores, and a maximum of 30 top scoring diverse 
ligand poses were returned for each of the compounds.  
 
Scoring function 
The docked conformations were further scored using 
various scoring functions available with Cerius2 [8]. The 
LigandFit algorithm [7] uses an internal scoring function, 
DockScore, to select and return dissimilar poses for each 
compound. DockScore is a simple force field based scoring 
function which estimates the energy of interaction by 
summing the ligand/protein interaction energy and the 
internal energy of the ligand. CFF force field [8] was used 
to resolve the van der Waals parameters for DockScore. 
The top DockScore pose was used for post docking 
scoring. The scoring was performed using a set of scoring 
functions as implemented in Cerius2 [8]. These included 
LigScore1, LigScore2, -PLP1, -PLP2, -PMF and 
DockScore available from the docking process. The putative 3D 
poses and score results were then stored as a SD file. Each 
docking was minimized, using DockScore, the only purely 
molecular mechanics based scoring function employed in this 
study, and this minimized pose was then presented to each of 
the other scoring functions, which were either knowledge based 
or regression based.  
 
Protein preparation 
The high-resolution (1.09 Å
) X-ray structure of human DHFR 
complex with SRI 9439 (PDBid code 1KMS) was imported into 
Cerius2  [8], and the ligand was extracted to leave a cavity. 
Thereafter, the docking simulations were carried out with and 
without cofactor NADPH and water molecules, to elucidate the 
role of NADPH and water molecules for the binding of DMDP 
derivatives. 
 
Hardware and software 
InsightII 2000.1 (http://www.accelrys.com) and Cerius2 [8] 
were used for molecular modeling on a SGI Origin 300 
workstation equipped with 4 * 600 MHz R12000 processor. 
 
Results and discussion: 
To date, several crystal structure of human DHFR in complex 
with different inhibitors have been reported viz 1DHF with 
folate  [9], 1 KMV with NADPH and (Z)- 6-(2-[2,5-
Dimethoxyphenyl] Ethen-1-yl)-2,4-Diamino-5- methylpyrido 
[2,3-D] Pyrimidine (SRI-9662), a lipophilic antifolate  [3], 
1KMS with NADPH and 6-([5-quinolylamino]methyl)-2,4-
diamino-5-methylpyrido [2,3-d]pyrimidine (SRI-9439), a 
lipophilic antifolate [3], 1DLS with methotrexate [10] and 
2DHF with 5-deazafolate  [9] etc. which provide information 
about the exact location and composition of inhibitor binding 
pocket and opportunity to use the enzyme in a functional 
conformation. We used X-ray structure of human DHFR in 
complex with SRI- 9439 and NADPH (PDBid code 1KMS) for 
the docking study. 
 
Validation of the docking method 
To ensure that the ligand orientation obtained from the docking 
studies were likely to represent valid and reasonable binding 
modes of the inhibitors, the LigandFit program docking 
parameters had to be first validated for the crystal structure 
(PDBid 1KMS). The ligand SRI-9439, in the conformation 
found in the crystal structure, was extracted and docked back to 
the corresponding binding pocket, to determine the ability of 
LigandFit to reproduce the orientation and position of the 
inhibitor observed in the crystal structure. Results of control 
docking showed that LigandFit determined the optimal 
orientation of the docked inhibitor, SRI-9439 to be close to that 
of the original orientation found in the crystal shown in Figure 
1a. 
 
The low RMS deviation of 0.502 Å between the docked and 
crystal ligand coordinates indicate very good alignment of the 
experimental and calculated positions especially considering the 
resolution of the crystal structure (1.09Å).  Bioinformation by Biomedical Informatics Publishing Group                                             open access 
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Interaction Modes between the DMDP derivatives and 
human DHFR 
The binding modes of DMDP derivatives in the binding 
site of human DHFR were identified using intermolecular 
flexible docking simulations by means of LigandFit 
program. All the compounds in the dataset were docked 
into the active site of human DHFR, using the same 
protocol. 
 
Figure 1b depicts the binding conformations of the DMDP 
derivatives in the binding pocket of the DHFR. The active 
site of DHFR comprises of mostly hydrophobic amino 
acids as Ile7, Val8, Trp24, Phe31, Phe34, Pro61, Val115 
and these amino acid residues are involved in strong 
hydrophobic interactions with the DMDP derivatives.  As 
expected, inhibitors used in this study bind to the same site 
like the docked ligand in the crystallographic complex. The 
inhibitors bind in a hydrophobic pocket adjacent to helix 
αB, with the 5-deazapteridine ring almost perpendicular to the 
5-quinolylamino group. The 5-deazapteridine ring of the 
inhibitors forms hydrophobic contacts with Val8, Ile7 and 
Phe31. The 5-deazapteridine rings of DMDP derivatives 
therefore bind to the human DHFR active site in an identical 
fashion, as reported in case of other inhibitors like methotrexate 
[10], SRI-9439 [3], SRI-9662 [3] etc. The DMDP derivatives 
bind to human DHFR mainly using the pterin moiety. As 
originally observed for methotrexate [10] and subsequently 
above inhibitors, DMDP derivatives bind with their 5-
deazapteridine rings flipped approximately 180
0 along the ring 
long axis relative to the position of folate in the active site. 
Thus, the opposite side of the pteridine ring is presented to the 
NADPH cofactor. The N1 and N2 nitrogen atoms of the 5-
deazapteridine rings form hydrogen bonds (shown in Figure 1 
as dotted lines) to oxygen atoms OE1 and OE2 of the side-chain 
of Glu30, which is highly conserved in the active site of all 
vertebral DHFRs [3, 9, 10]. 
 
 
Figure 1: (a) Conformation of SRI-9439 crystal structure (red) as compared to the docked conformation of   SRI-9439 (Yellow) 
with cofactor NADPH (green). Amino acid residues are presented in magenta, (b) The docked 3-D structures of DMDP 
derivatives, (c) Docked Confirmation of  Compound 63 and (d) Docked Confirmation of  Compound 29. Bioinformation by Biomedical Informatics Publishing Group                                             open access 
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The binding mode of the most active compound 63 has 
been shown in Figure 1c. As expected, compound 63 bind 
to the DHFR active site in the similar conformation as 
other known DHFR inhibitors (SRI-9662, SRI-9439, 
methotrexate) which mainly bind using the pterin moiety 
and this moiety is presented to nicotinamide ring of 
cofactor NADPH. This pterin ring is involved in π-π 
stacking interactions with the nicotinamide ring of 
NADPH. This stacking interaction is very important and 
has been conserved in most of the DHFR’s for which 
crystal structures have been solved with NADPH and 
inhibitors in ternary complex with the enzyme. The chloro 
substituted naphthyl ring of compound 63 makes 
significant hydrophobic contact with Leu 22, Phe 31 and 
Pro 61 of the DHFR active site leading to enhanced 
inhibition of the enzyme when compared with compound 
29 (least active) where chloro substituted naphthyl ring is 
substituted with phenyl ring with methoxy substitution at 2 
and 5 positions leading to decreased hydrophobicity of the 
compound and hence low amount of inhibition as shown in 
Figure 1d. The two amino group of the pterin ring makes 
strong hydrogen bond with main chain oxygen atom of Ile 
7 and Val 115 and side chain oxygen atom of Glu 30. 
These particular interactions play a very important role in 
DHFR inhibition and need to be present for good inhibition 
by the inhibitors. Moreover, any bulkier substitution at R1 
position of the DMDP derivatives may lead to steric 
clashes with Phe 34 and the cofactor NADPH and that is 
why compound 29, 45, 50, 51 are not very much active, 
whereas compounds with methyl substitution are more 
active as in case of compound 63, is shown in Figure 1c. 
 
Correlation between docking scores and inhibitory 
activity 
The predicted inhibitory activity of DMDP derivatives as 
inhibitors on the basis of dock score is listed in Table 1 
(supplementary material). Linear regression analysis was 
performed to explore whether the docking scores could be 
correlated with the experimental activities. The equation was 
obtained for the inhibitory activities represented as pIC50 
values, using the Dock score, Ligscore1, Ligscore2, -PLP1, -
PLP2, -PMF and Consensus score as the variable descriptors. A 
model with the correlation coefficient (r
2) of 0.356 was 
obtained for 78 compounds using the Equation 1 under 
supplementary material. 
 
Removal of 5 compounds [Comp 29, Comp 32, Comp 46, 
Comp 48, and Comp 49] identified as outliers from the docking 
dataset yield a better model with correlation coefficient (r
2) of 
0.499 was obtained for 73 compounds. This rather good 
correlation demonstrates that the binding conformations and 
binding models of the DMDP derivatives with human DHFR 
are reasonable shown in Figure 2. Activity can be best 
explained for rest of the compounds using the Equation given in 
supplementary material.  
 
Conclusion: 
In this work, molecular docking studies were carried out to 
explore the binding mechanism of DMDP derivatives to the 
human DHFR enzyme to enable the design of new DMDP-
based human DHFR inhibitors. Both the binding conformation 
of DMDP and their binding free energies were predicted by 
molecular docking. The binding free energies of these 
compounds to human DHFR were found to have a good 
correlation with the experimental inhibitory activities. The 
results provide insight into the structural requirement for the 
activity of this class inhibitor and the most favorable binding 
mode of the top – ranking compounds will be useful in 
designing new DMDP derivatives as human DHFR inhibitors. 
 
 
Figure 2: A correlation for binding conformations and binding models of the DMDP derivatives with human DHFR.Bioinformation by Biomedical Informatics Publishing Group                                             open access 
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Supplementary material 
 
Equations 
 
                  →           (1) 
 
                  →          (2) 
 
 
DMDP derivatives with modifications 
N
N N
N
NH2
NH2
H
R6
R5
R4
R3 R2
R1
 
DMDP derivatives with modifications at the 5 position (R1) and 
substitutions on the phenyl group (R2 through R6). 
Derivative 
no. 
R1 R2  R3  R4  R5  R6 
Exp. 
activity 
(-log 
IC50) 
Predicte
d activity 
(pIC50) 
Dock 
score 
Comp. 1  -CH3 -OCH2CH3 -H -H  -OCH2CH3 -H 5.638  7.286  66.403 
Comp. 2  -CH3 -OCH3 -H -H -OCH3 -H 6.000  7.124  71.728 
Comp. 3  -CH3 -OCH3CH3 -H -H  -OCH2CH3 -H 6.00  6.292  58.726 
Comp. 4  -CH3 -CH3 -H -H -OCH3 -H 6.824  6.823  64.241 
Comp. 5  -CH3 -CH3 -H -Br  -H  -CH3 5.721 6.620  59.402 
Comp. 6  -CH2CH3 -OCH3 -H -H -OCH3 -H 6.000  6.071  63.456 Bioinformation by Biomedical Informatics Publishing Group                                             open access 
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Comp. 7  -CH3 -OCH3 -H -H  -CH3 -H 6.523  6.476  62.092 
Comp. 8  -CH3 -OCHF2 -H -H  -H  -H  6.558 6.694  64.709 
Comp. 9  -CH3 -F -H  -H  -CH3 -H 6.602  7.773  60.858 
Comp. 10  -CH3 -Cl -H  -CH3 -H -CH3 6.071 7.661  63.186 
Comp. 11  -CH3  -Cl  -H  -H  -H  -H  6.921  7.069  60.561 
Comp. 12  -CH2CH3 -OCH3 -H -H  -CH3 -H 6.432  6.093  60.749 
Comp. 13  -CH3 -F -H  -H  -F  -H  7.161  6.105  57.057 
Comp. 14  -CH3 -OCH3 -H -C6H5 -H -H  7.167  7.470  71.621 
Comp. 15  -CH3 -CH3 -H -H  -CH3 -H 7.244  7.635  64.671 
Comp. 16  -CH3 -Cl -H  -H  -CH3 -H 7.357  7.341  63.469 
Comp. 17  -CH3  -Cl  -H  -F  -CH3 -H 7.481  7.595  61.363 
Comp. 18  -CH3 -H -H  -Cl  -H  -H  7.569  7.663  63.152 
Comp. 19  -CH3 -OCH3 -H -H  -CF3 -H 7.444  8.122  62.530 
Comp. 20  -CH3 -H -OCH3 -H -OCH3 -H 7.824  7.218  69.492 
Comp. 21  -CH3 -CH3 -H -H  -F  -H  7.721 7.281  63.786 
Comp. 22  -CH3  -H  -Cl  -H  -H  -H  7.77  7.637  62.575 
Comp. 23  -CH3 -H -H 
-
OCHF
3
-H -H  7.699  7.734  64.907 
Comp. 24  -CH3 -H -OCH3
-
OCH3
CH3
-H -H  7.553  7.434  69.597 
Comp. 25  -CH3 -H -OCH3
-
O(CH3
) 3CH3
-H -H  7.824  6.985  57.316 
Comp. 26  -H  -H  -OCH3 -OCH3 -OCH3 -H 5.409  5.802  59.546 
Comp. 27  -CH3 -H -F  -OCH3 -H -H  7.854  8.330  63.815 
Comp. 28  -CH3 -CH3 -H -Cl  -H  -H  8.553 7.522  63.298 
Comp. 29 
-
CH2OCH
3
-OCH3 -H -H -OCH3 -H 4.509  *  * 
Comp. 30  -CH3 -H -OCH3 -H -OCH3 -H 8.060  7.485  68.155 
Comp. 31  -CH3 -OCH3 -H -Cl  -CH3 -H 8.000  6.413  63.266 
Comp. 32  -H  -H  -H  -Cl  -H  -H  6.174  *  * 
Comp. 33  -CH3 -Cl -H  -H  -Cl  -H  8.097  6.872  64.982 
Comp. 34  -CH3 -CH3 -H -H  -Cl  -H  8.215 8.007  67.787 
Comp. 35  -CH3 -H -Cl  -CH3 -H -H  8.174  8.105  57.504 
Comp. 36  -CH3 -H -OCH3 -OCH3 -H -H  8.292  8.307  69.990 
Comp. 37  -CH3  -H  -CH3 -Br -H  -H  8.215  8.478  59.323 
Comp. 38  -CH3 -CH3 -H -Br  -H  -H  8.229 8.009  61.589 
Comp. 39  -CH3 -Br -H  -H  -Br  -H  8.337  6.811  63.024 
Comp. 40  -CH3 -CH3 -Cl -H  -H  -H  8.284 7.243  63.173 
Comp. 41  -CH3 -H -Br  -CH3 -H -H  8.432  7.974  63.701 
Comp. 42  -CH3  -H  -OCH3 -H -CF3 -H 8.260  6.870  64.843 
Comp. 43  -CH3 -H -OCH3 -OCH3 -OCH3 -H 8.328  7.667  51.788 
Comp. 44  -CH3 -H -Cl  -Cl  -H  -H  8.301  7.882  66.091 
Comp. 45  -
CH2OCH3
-H -OCH3 -OCH3 -H -H  5.215  5.942  49.975 
Comp. 46  -CH3 -F -H  -H  -CF3 -H 8.387  *  * 
Comp. 47  -CH3 -OCH3 -H -H  -CF3 -H 8.569  6.810  64.199 
Comp. 48  -CH2CH3 -OCH3 -H -H  -CF3 -H 8.444  *  * 
Comp. 49  -CH3 -Br -H  -H  -CF3 -H 8.495  *  * 
Comp. 50  -
CH2OCH3
-H -OCH3 -OCH3 -OCH3 -H 5.886  5.878  49.447 
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N
N
Comp. 51  Comp. 51  -
CH2OCH3
-H  -H -H  -H  -Cl  -Cl  -H  -H  -H  -H  5.585  5.585  6.830  6.830  58.839  58.839 
   
N
N
-
CH2OCH3
NH2 CH3
N
N
H
X
NH2  
DMDP derivatives with Complex ring substitutions attached to the CN Bridge. 
  
  X      
Comp. 52 
 
6.149 7.549  69.206 
Comp. 53 
 
6.848 6.779  70.376 
Comp. 54 
 
5.276 6.285  61.559 
Comp. 55 
 
8.000 7.591  65.888 
Comp. 56 
 
5.469 5.377  58.956 
Comp. 57  N
 
7.921 7.851  65.686 
Comp. 58 
 
6.086 6.804  69.061 
Comp. 59 
 
8.174 7.916  62.960 
Comp. 60  N
 
8.149 7.720  65.791 
Comp. 61 
 
8.208 7.532  64.529 
 Bioinformation by Biomedical Informatics Publishing Group                                             open access 
www.bioinformation.net                                                                   Hypothesis 
______________________________________________________________________________ 
 
ISSN 0973-2063 (online) 0973-8894 (print)                                                                        
Bioinformation 3(4): 180-188 (2008) 
Bioinformation, an open access forum 
© 2008 Biomedical Informatics Publishing Group 
 
187
Comp. 62 
 
8.367 7.850  61.467 
Comp. 63 
Cl
 
8.699 7.649  67.200 
Comp. 64 
N 
8.398 7.114  70.145 
Comp. 65  N
 
8.367 7.743  66.922 
Comp. 66 
 
8.42 7.614  59.461 
Comp. 67 
 
4.596 5.601  62.102 
  N
N N H2N
NH2 CH3
CH2 X
R6 R5
R4
R3 R2  
DMDP derivatives involving modification of the bridge molecules X 
  
  X R2  R3  R4  R5  R6      
Comp. 68  -CH3 -H -OCH3 -H -OCH3 -H 6.004  6.868  64.163 
Comp. 69  -S  -H  -H  -OCH3 -OCH3 -H 6.357  6.140  60.714 
Comp. 70  -S  -H  -OCH3 -OCH3 -OCH3 -H 5.921  5.363  45.562 
Comp. 71  -S  -H  -H  -H  -OCH3 -H 6.301  6.424  61.898 
Comp. 72  -S  -H  -H  -Cl  -H  -H  6.229  7.667  57.005 
Comp. 73  -S  -OCH3 -H -H -OCH3 -H 5.602  5.416  55.779 
Comp. 74  -S  -H  -H  -H  -Cl  -H  6.377  6.479  55.430 
Comp. 75  -S     
-1-
Napht
hyl 
   6.357  6.103  40.676 
Comp. 76  -CH3 -OCH3 -H -H -OCH3 -H 5.569  6.322  61.723 
Comp. 77  -S  -H  -H  -H  -CH3 -H 6.071  7.095  60.090 
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N
N N H2N
NH2 CH3
N
H
R2
R5
 
DMDP derivatives in the series involving substitutions at the R2 and R5 positions. 
  
  R2 R5      
Comp.78 -O(CH2) 2CH3 -O(CH2) 2CH3 5.137 5.603  57.254 
Table 1: DMDP derivatives with modifications and Experimental activities and Predicted activities with DOCKSCORE. 
*activity for compounds was not predicted as they are found as outliers. 